Pay in 4 interest-free payments of $7.22 Learn more
Ships within 48 hours · Estimated delivery Oct 6 - Oct 11
Information in the report is treated as confidential
Tirzepatide, the first dual GIP/GLP-1 agonist, received US Food and Drug Administration (FDA) approval in 2023 (Zepbound ) after demonstrating superior efficacy over semaglutide, including 22% weight loss and enhanced glycaemic control [76,77,78]
When foodespecially glucose and lipidsenters the digestive tract, these K-cells sense the nutrients and secrete GIP into the bloodstream
Check with your doctor immediately if any of the following side effects occur while taking semaglutide: More common side effects anxiety bloating blurred vision chills cold sweats confusion constipation cool, pale skin cough darkened urine depression diarrhea difficulty swallowing dizziness fast heartbeat fever headache increased hunger indigestion large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs loss of appetite nausea nervousness nightmare pain in the stomach, side, or abdomen, possibly radiating to the back seizures skin rash slurred speech tightness in the chest trouble breathing unusual tiredness or weakness vomiting yellow eyes or skin Other side effects of semaglutide Some side effects of semaglutide may occur that usually do not need medical attention
doi: 10.4103/1673-5374.205105 99
